These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 34040179)

  • 1. The breast is yet to come: current and future utility of circulating tumour DNA in breast cancer.
    Davidson BA; Croessmann S; Park BH
    Br J Cancer; 2021 Sep; 125(6):780-788. PubMed ID: 34040179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.
    Chung JH; Pavlick D; Hartmaier R; Schrock AB; Young L; Forcier B; Ye P; Levin MK; Goldberg M; Burris H; Gay LM; Hoffman AD; Stephens PJ; Frampton GM; Lipson DM; Nguyen DM; Ganesan S; Park BH; Vahdat LT; Leyland-Jones B; Mughal TI; Pusztai L; O'Shaughnessy J; Miller VA; Ross JS; Ali SM
    Ann Oncol; 2017 Nov; 28(11):2866-2873. PubMed ID: 28945887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of circulating tumour DNA (ctDNA) from the liquid biopsy results: Findings from an observational cohort study.
    Myint KZY; Shimabuku M; Horio R; Kaneda M; Shimizu Y; Taguchi J
    Cancer Treat Res Commun; 2023; 35():100701. PubMed ID: 37094468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumour DNA testing in metastatic breast cancer: Integration with tissue testing.
    Ranghiero A; Frascarelli C; Cursano G; Pescia C; Ivanova M; Vacirca D; Rappa A; Taormina SV; Barberis M; Fusco N; Rocco EG; Venetis K
    Cytopathology; 2023 Nov; 34(6):519-529. PubMed ID: 37640801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted mutation detection in breast cancer using MammaSeq™.
    Smith NG; Gyanchandani R; Shah OS; Gurda GT; Lucas PC; Hartmaier RJ; Brufsky AM; Puhalla S; Bahreini A; Kota K; Wald AI; Nikiforov YE; Nikiforova MN; Oesterreich S; Lee AV
    Breast Cancer Res; 2019 Feb; 21(1):22. PubMed ID: 30736836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
    Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
    PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applications of Circulating Tumor Cells and Circulating Tumor DNA in Precision Oncology for Breast Cancers.
    Addanki S; Meas S; Sarli VN; Singh B; Lucci A
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liquid biopsy in breast cancer: A comprehensive review.
    Alimirzaie S; Bagherzadeh M; Akbari MR
    Clin Genet; 2019 Jun; 95(6):643-660. PubMed ID: 30671931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating tumor DNA: current challenges for clinical utility.
    Dang DK; Park BH
    J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35703177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tumour DNA alterations: emerging biomarker in head and neck squamous cell carcinoma.
    Huang X; Duijf PHG; Sriram S; Perera G; Vasani S; Kenny L; Leo P; Punyadeera C
    J Biomed Sci; 2023 Aug; 30(1):65. PubMed ID: 37559138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumor DNA in early-stage breast cancer: new directions and potential clinical applications.
    Croessmann S; Park BH
    Clin Adv Hematol Oncol; 2021 Mar; 19(3):155-161. PubMed ID: 33739964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection.
    Cani AK; Dolce EM; Darga EP; Hu K; Liu CJ; Pierce J; Bradbury K; Kilgour E; Aung K; Schiavon G; Carroll D; Carr TH; Klinowska T; Lindemann J; Marshall G; Rowlands V; Harrington EA; Barrett JC; Sathiyayogan N; Morrow C; Sero V; Armstrong AC; Baird R; Hamilton E; Im SA; Jhaveri K; Patel MR; Dive C; Tomlins SA; Udager AM; Hayes DF; Paoletti C
    Mol Oncol; 2022 May; 16(10):1969-1985. PubMed ID: 34866317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of circulating tumor DNA in breast cancer.
    Zhao Y; Sheng M; Zheng L; Xiong D; Yang K; Luo Y
    Breast J; 2020 Sep; 26(9):1797-1800. PubMed ID: 32052544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
    Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
    Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Liquid biopsy in colorectal cancer : An overview of ctDNA analysis in tumour diagnostics].
    Haupts A; Roth W; Hartmann N
    Pathologe; 2019 Dec; 40(Suppl 3):244-251. PubMed ID: 31797045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer.
    van 't Erve I; Greuter MJE; Bolhuis K; Vessies DCL; Leal A; Vink GR; van den Broek D; Velculescu VE; Punt CJA; Meijer GA; Coupé VMH; Fijneman RJA
    J Mol Diagn; 2020 Dec; 22(12):1430-1437. PubMed ID: 32961317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liquid Biopsies for Monitoring Temporal Genomic Heterogeneity in Breast and Colon Cancers.
    Venesio T; Siravegna G; Bardelli A; Sapino A
    Pathobiology; 2018; 85(1-2):146-154. PubMed ID: 28614831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultradeep targeted sequencing of circulating tumor DNA in plasma of early and advanced breast cancer.
    Chin YM; Takahashi Y; Chan HT; Otaki M; Fujishima M; Shibayama T; Miki Y; Ueno T; Nakamura Y; Low SK
    Cancer Sci; 2021 Jan; 112(1):454-464. PubMed ID: 33075187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma DNA as a "liquid biopsy" incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast cancer.
    Chamberlin MD; Wells JD; Shee K; Bean JR; Marotti JD; Wells WA; Trask HW; Kolling FW; Bhatt A; Kaufman PA; Schwartz GN; Gemery JM; McNulty NJ; Tsapakos MJ; Barth RJ; Arrick BA; Gui J; Miller TW
    Breast Cancer Res Treat; 2020 Aug; 182(3):665-677. PubMed ID: 32562118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liquid Biopsy in Endometrial Cancer: New Opportunities for Personalized Oncology.
    Muinelo-Romay L; Casas-Arozamena C; Abal M
    Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30087246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.